Among milk proteins, the concentration of β-casein is the second highest among all proteins in cow milk (Table 1) [5]. With respect to α_s1- and α_s2-casein compositions in bovine milk, it contains 38% α_s1- and 12% α_s2-casein, where α_s1-casein has been reportedly associated with cow milk allergy [13,15,16,17]. In contrast, β-casein content of goat milk is the highest (54.8%) among all its caseins (Table 1) [7], and caprine milk contains significantly higher α_s2-casein than bovine milk. Many previous reports have shown that this unique compositional characteristic of caprine milk is highly correlated with the therapeutic and hypoallergenic properties of its milk in infants and especially in CMPA patients [14,17,18,19]. Amalfitano et al. (2020) [1] reported that in terms of percentage of milk N, the genotypes of CSN3 notably affected all the casein fractions, whereas the BLG genotypes had a much greater influence on most non-casein traits. The genotypes of the CSN2 gene exerted an appreciable effect on α_S2-CN and not β-CN. For an amount (g/L) of β-CN, the effect of breed was revealed to be significant (12%), whereas breed was almost insignificant before the inclusion of genotypes.

Since the potential relationship has been shown between A2 milk consumption and the health of milk consumers, it is essential to understand the genetic variants of β-casein and their biochemical and physiological functionalities. Thirteen β-casein genetic variants have been identified, including A1, A2, B, C, D, E, F, H1, H2, I and G (Table 2), which have been reviewed by several authors [14,20,21]. Givens et al. (2013) [22] showed that β-casein in UK retail milk comprises approximately 0.58, 0.31, 0.07 and 0.03 A2, A1, B and C protein variants, respectively. The A4 allele was found in Korean native cattle, while the nucleotide substitution has not been recognized yet. Among the β-casein genetic variants, the most common forms of β-casein in dairy cow breeds are A1 and A2, whereas B variant is less common, and A3 and C alleles are rare [23]. The difference between A1 and A2 bovine milk is that there is an amino acid substitution at the 67th position of the protein chain, where proline of A2 variant is substituted by histidine of variant A1 [24,25], meaning that A1 milk has histidine, while A2 milk has proline in position 67 of the β-casein.

On the other hand, A2 milk prevents the breakdown at the amino acid chain at position 67 due to proline and generates another peptide called BCM-9 [26,27]. These two variants of β-casein carried by dairy cattle are the most common and popular dairy cow breeds in worldwide basis. In addition to A1 variant of β-casein, there are several other β-casein variants that have the same proline substitutions at the 67th position of the amino acid chain like A1 β-casein does, which are B, C, F and G variants of β-casein (Table 2). Using two methods—high-resolution melting (HRM) and rhAmp^® SNP genotyping—Giglioti et al. (2020) [28] found that the limits of detection for A1 in A2 samples were 10% (100 copies) and 2% (10 copies) for HRM and rhAmp, respectively. Although both techniques were specific in differentiating between A1 and A2 alleles, they recommended rhAmp genotyping testing over HRM because of its enhanced sensitivity for A1.

The northern European breeds of dairy cow including Holstein, Friesian, Ayrshire and British Shorthorn generally produce milk containing high A1 β-casein. On the other hand, dairy cow breeds from the Channel Islands and southern France, such as Guernsey, Jersey, Simmental, Charolais and Limousin cows, produce A2 β-casein milk [13,14]. Priyadarshini et al. (2018) [7] reported that the milk of Indian crossbred and European breeds cattle contain the A1 protein variant, while those of the indigenous cows and buffaloes in India and other Asian countries mostly have the A2 protein variant. The molecular mass of casein is approximately 18–25 kDa. As casein molecule is developed through posttranslational modifications and alternative splicing of the gene product and genetic polymorphisms, it is quite heterogeneous in nature [9,12,13].

Beta-casomorphins (BCMs) are peptide chains containing 4–11 amino acids (aa), derived from β-casein molecules. All these BMC peptides begin with tyrosine amino acid residue in position 60 [27]. Upon digestion, A1 β-casein milk releases BCM-7, which is a bioactive peptide 7 amino acid (Tyr-Pro-Phe-Pro-Gly-Pro-Ile), which possess morphine-like activity [29]. This BCM-7 exhibits several bioactivities such as a strong opioid activity [30], stimulating human lymphocyte T proliferation in vitro [31] and cytomodulatory properties [32].

The sequence of BCM-7 is located at positions 60–66 of the bovine beta-casein AA chain [14]. The BCM-7 is generated with digestive actions of pepsin, pancreatic elastase and leucine aminopeptidase by in vitro gastrointestinal digestion of β-casein A1 and B (but not A2) [33,34,35]. The peptide bond between Ile and His is cleaved by elastase, which releases the carboxyl terminus of BCM-7 [14]. The amino terminal of this peptide can be released by the required enzymes of pepsin and leucine aminopeptidase (Figure 1) [34]. Nguyen et al. (2021) [35] observed that β-CM7 was not released after gastrointestinal digestion of heated A2A2 milk, and β-CM7 was released after gastrointestinal digestion of heated A1A1 and A2I milk. This difference occurred by the mutation accounts for the polymorphism of a single nucleotide at codon 67 of the β-casein gene: CCT (A2, proline) CAT (A1, histidine) [36]. A conformational difference in the expressed protein by the secondary structure may be attributable to the difference in AA sequence. Hydrolyzed variant A1 β-casein of bovine milk contained four times higher content of BCM-7 than in A2 milk [14]. Traces of BCM-7 were found in fresh milk due to the absence of proteolysis [37]. Nevertheless, precursors of BCMs were observed in Cheddar, Swiss, Limburger, Blue and Brie cheeses, while BCMs were not existed due to the possible degradation by enzymatic proteolysis caused by the starter culture or the possible presence of undetectable amounts of these peptides [38]. Large quantities of BCM-like and morphiceptin-like activities in infant formulas were also identified [38].

Using liquid chromatography coupled with electrospray ionization mass spectrometry (LC/ESI-MS), Petrat-Melin et al. (2015) [22] confirmed the identity and purity of the isolated β-CN variants. The β-CN is assumed to be 40% of total CN, whereby the amount of β-CN was calculated by the purification process. With milk composition data of Milkoscan combined with protein quantification by AA analysis, the yields of the four isolated β-CN variants, A1, A2, B and I, were estimated, which were between 5 and 20% of total β-CN originally present in the milk samples, and the purity relative to total protein determined by LC/ESI-MS varied from 89.2 to 93.2% [22]. After 60 min of pepsin digestion, the degree of hydrolysis (DH) for the β-CN variants showed approximately 3% with an enzyme: substrate ratio of 1:200 in the reaction (Table 3). The DH increased to around 20% after 5 min digestion with pancreatic enzymes, and DH became close to 50% after 120 min for all β-CN variants, in the order of DH being A 1 > A 2 > I > B. The authors indicated that DH could be converted to a mean length of peptides by 100%/DH as shown in Table 3.

Gastrointestinal digestion or hydrolysis of bovine milk proteins in vitro or in vivo has shown to generate the bioactive peptide beta-casomorphin 7 (BCM-7) from β-casein variants A1 and B, whereas the peptide is not produced from variant A2 milk. It has been reported that the BCM-7 level is four-fold higher in variant A1 of β-casein digested proteolyzed milk than the BCM-7 level of A2 milk ([15,39]. Many dairy cow breeds commonly have variants A1 and A2 of β-casein [40].

Epidemiological evidence has revealed that consumption of A1 β-casein is correlated with human disease, indicating that BCM-7 from A1 bovine milk can be a risk factor for type 1 diabetes, human ischemic heart disease (IHD), atherosclerosis and sudden infant death syndrome [8,9,10,11,38]. The World Health Organization (WHO) suggested the risk factor data for several diseases and mortality data attributed to BCM-7 from A1 bovine milk. The populations consuming high levels of β-casein A2 in the milk appeared to have a lower occurrence of type 1 diabetes [41], cardiovascular disease and a possible sudden infant death syndrome [12,13,14]. Furthermore, a higher level of BCM-7 consumption is associated with neurological disorders, such as autism and schizophrenia. Deeper researches on protein polymorphism are necessary to verify the range and nature of BCM-7 interactions with the human gastrointestinal tract and whole organism.

A high intake of A1 β-casein is shown to be a risk factor for IHD [10], and the association was shown between IHD rate and β-casein A1 consumption in males of 30–69 old for 16 countries (Australia, France, Iceland, Austria, Canada, Denmark, Finland, Norway, Scotland, Sweden, Israel, Japan, New Zealand, West Germany, United Kingdom and USA) [10]. In addition, A1 β-casein consumption was found to cause atherosclerosis or hypercholesterolemia in many species’ animal research such as pigs, rabbits, rodents and monkeys [10,39]. In a multi-center, randomized controlled study, effects of cow’s milk β-casein variants on symptoms of milk intolerance were observed in Chinese adults [42]. The physiological effect of BCM-7 in A1 β-casein may have an influence on the oxidation and/or peroxidation of a lipid component of low-density lipoprotein (LDL) [40].

A significant association was also found epidemiologically between the intake of A1 milk and the incidence of diabetes mellitus type 1 (DM-1) [10,11,39], which was not observed in A2 milk consumption. In an evaluation of the annual cow milk protein consumption and DM-1 cases in children of 0–14 year old in 10 countries, it was observed that the intake of total protein was not correlated with the incidence of DM-1 (r = 0.402), whereas consumption of the β-casein A1 variant showed a high correlation (r = 0.726) [43]. Furthermore, the correlation between the consumption of β-casein A1 + B and the occurrence of DM-1 was even higher (r = 0.982). The A1 β-casein consumption across 16 countries was associated strongly (r = 0.75) with the occurrence of DM-1. The BCM-7 released by β-casein reportedly inhibit the proliferation of in vitro human intestinal lymphocyte. This type of immune suppressant may influence the development of intestinal immune tolerance and may suppress defense mechanisms towards enteroviruses, where both cases may be implicated in the etiology of DM-1 [11,43]. On the other hand, Thakur et al. (2020) [44] found that feeding A1 or A2 cow-milk-derived casein hydrolysates did not cause any deteriorative effect on the blood biochemical profile and histopathology of major organs such as heart, liver and kidney.

Milk is one common factor to develop the sudden infant death syndrome (SIDS) in all children [8], which causes the death of infants during the first year of the life, beginning at the end of the first month [40]. After BCMs are absorbed from the gastrointestinal tract, these compounds can cross over the blood–brain barrier because of the immaturely developed central nervous system in infants. Depression of the brain-stem respiratory centers can occur in infants due to the ingestion of the opioid peptides like BCM-7, which is derived from A1 milk. This condition can lead to infant death due to abnormal respiratory control and vagal nerve development [14]. The BCM immunoreactivity was found in the brain stem of the human infant. BCM-7 can be absorbed by infants due to immature gastrointestinal tract [44], where significant elevations of BCM-7 levels in infant patient’s blood [42,43] and in urine showing autism, schizophrenia and postpartum psychosis [45].

CMPA sometimes can be confused with lactose intolerance (LI), where LI is not associated with the immune system of the body. CMPA and LI share some signs and symptoms, including stomach and gut problems such as wind and diarrhea, while CMPA usually occurs in babies younger than 1 year old, LI is very rare in children under 5 years of age [46]. CMPA is a type of milk allergy of a baby’s immune responses to bovine milk protein, causing allergic symptoms such as digestive system (diarrhea, vomiting, constipation and reflux), respiratory system (noisy breathing, coughing, runny nose) and the skin (rash, hives, dry, scaly or itchy skin) [46].

Many studies have reported that consumption of A1 β-casein bovine milk caused CMPA, including increased gastrointestinal inflammation, elevated digestive discomfort after milk ingestion, delayed transit, which are metabolically linked to type 1 diabetes, cardiovascular disease, atherosclerosis and decreased cognitive processing speed and accuracy [19,20,21]. Since these digestive discomforts and some symptoms of lactose intolerance may stem from the ingestion of A1 β-casein milk, the adversary gastrointestinal problems of A1 β-casein milk can be alleviated and resolved by consumption of only A2 β-casein milk. The A2 cow milk, therefore, has emerged and recommended for remedy of CMPA.

There are differences in protein structures and amino acids makeup in milk composition within and between dairy species, such as cow and goats. There are two variants of αS-casein—α_s1- and α_s2-casein—where α_s1-casein is linked to cow milk allergy. Since cow milk contains α_s1-casein as its dominant protein, goat milk has been recommended often as a cure for cow milk allergy [15,16]. The dominant protein in goat milk is α_s2-casein, not α_s1-casein, which makes goat milk less allergenic. The differences in amino acid composition between α_s1- and α_s2-casein in bovine and caprine milk may be accountable for the allergenicity of cow milk with α_s1-casein in contrast to the hypoallergenicity of goat milk with α_s2-casein [32]. On the other hand, the advantage of α_s1-casein is that it can form firmer curds so that it increases cheese yield, which would be related to the economics of dairy goat farming, not for the remedy of CMPA.

Much literature has shown that goat milk has been used for hypoallergenic and therapeutic foods in infants and patients who suffer from CMPA. Compared to cow or human milk, caprine milk reportedly possesses great advantages, including high digestibility, distinct alkalinity, high buffering capacity and certain therapeutic values in medicine and human nutrition [17,18,19]. Major clinical symptomology of CMPA patients to bovine milk proteins include rhinitis, diarrhea, vomiting, asthma, anaphylaxis, urticaria, eczema, chronic catarrh, migraine, colitis stomach ulcer, hayfever, epigastric distress and abdominal pain, etc. [15,16,17,47,48,49,50,51,52]). Over 20 years French clinical studies with CMPA patients, Sabbah et al. (1997) [53] concluded that substitution with goat milk was followed by “undeniable” improvements in healing CMPA symptoms. Children who are allergic to cow milk were extensively studied in other clinical trials in France, where the results revealed that 93% of the children treated with goat milk had positive results against CMPA. The researchers recommended goat milk as a valuable therapeutic alternative in child nutrition because of its reduced allergenicity and better digestibility than cow milk [54,55,56]. Therefore, it has been shown that caprine milk has great therapeutic remedy functions for CMPA patients, in addition to the efficacy of A2 bovine milk for the same cow milk allergy.

Due to the health benefits of A2 β-casein containing milk, there is now an actual dairy cow herd existing in California, which can produce milk with only A2 β-casein. Production of this type of milk may take advantage in the market place to help people with health concerns to drink more of their recommended three glasses of milk per day [57,58]. Likewise, a creamery in Ohio is now distributing A2 milk in 2 L cartons in Farmers Markets of West Virginia and stores in the Washington D.C. area. Additionally, A2 milk is now on the store dairy shelves of the Kroger Store in Barboursville, West Virginia at about USD 4.20 per half gallon, which is twice the price of regular store milk. Active sales of A2 milk have also been reported from Charlotte, North Carolina. Most encouraging is trade magazine advertisement of Holstein bulls with the A2/A2 beta casein genetics such as for “Dun-Did Bush Wacker”-ET A2/A2 by Triple-Hil Sires, EX-90 3 yr/aAa: 354/62/Smithsburg, Maryland in the leading Pennsylvania dairy magazine Farmshine in their 24 January 2020 issue [59]. A feature article in the North American edition of the International Holstein Hub magazine discusses the A2 phenomenon in length [60] and stated “While the health benefits of A2 milk may not be entirely certain, it is clear that a niche market has been created that commands a price premium. With a growing supply of A2A2 bulls to select from, breeding cows to fill that niche becomes an attractive proposition. Indeed, with the A2A2 bulls ranking as high as the Nr. 3 on the TPI charts, then breeding for A2 does not require a lot of compromise in other areas”. Thus, there maybe now the beginning of “taylor-made”, the A2 milk, coming to the rescue of consumers.

In order to test dairy cows and market milk containing only the A2 variant of β-casein, New Zealand established a company called the “A2 Corporation Ltd.” in 2000. A DNA test kit has been developed by this corporation, where the test kit can determine if the animal belongs to A1 or A2 or a combination of both, by analyzing a hair plucked from a cow’s tail [14]. The selective distribution of bull semen is the easiest way to use the desirable β-casein A2 genotypes. The herds of dairy cattle producing milk with A2 variant only can be developed by this method. As a premium brand of cow milk, this specific A2 variant of β-casein milk has been commercially marketed in New Zealand and Australia since 2003, where this offers the consumers a natural choice of A2 milk. The same corporation has also launched marketing this healthy and therapeutically advantageous A2 milk in Asia and the United States [14].

References
1. Amalfitano, N.; Stocco, G.; Maurmayr, A.; Pegolo, S.; Cecchinato, A.; Bittante, G. Quantitative and qualitative detailed milk
protein profiles of 6 cattle breeds: Sources of variation and contribution of protein genetic variants. J. Dairy Sci. 2020, 103,
11190–11208. [CrossRef]
2. Businco, L.; Bellanti, J. Food allergy in childhood. Hypersensitivity to cow’s milk allergens. Clin. Exp. Allergy 1993, 23, 481–483.
[CrossRef]
3. Park, Y.W.; Haenlein, G.F.W. Therapeutic and Hypo-Allergenic and Bioactive Potentials of Goat Milk, and Manifestations of Food
Allergy. In Handbook of Milk of Non-Bovine Mammals, 2nd ed.; Park, Y.W., Haenlein, G.F.W., Wendorff, W.L., Eds.; Wiley-Blackwell
Publishers: Oxford, UK, 2017; pp. 151–180.
4. Host, A.; Husby, S.; Osterballe, O. A prospective study of cow’s milk allergy in exclusively breast—Fed infants. Acta Paediatr.
1988, 77, 663–670. [CrossRef] [PubMed]
5. Park, Y.W. Goat milk-Chemistry and Nutrition. In Handbook of Milk of Non-Bovine Mammals, 2nd ed.; Park, Y.W., Haenlein, G.F.W.,
Wendorff, W.L., Eds.; Wiley-Blackwell Publishers: Oxford, UK, 2017; pp. 42–83.
6. Sodhi, M.; Mukesh, M.; Kataria, R.S.; Mishra, B.P.; Joshii, B.K. Milk proteins and human health: A1/A2 milk hypothesis. Indian J.
Endocrinol. Metab. 2012, 16, 856. [CrossRef]
7. Priyadarshini, P.; Mishra, C.; Mishra, B.; Swain, K.; Rout, M.; Mishra, S.P. Impact of milk protein on human health: A1 verses A2.
IJCS 2018, 6, 531–535.
8. Sun, Z.; Cade, J.R.; Fregly, M.J.; Privette, R.M. Beta casomorphin induces Fos-like immune reactivity in discrete brain regions
relevant to schizophrenia and autism. Autism 1999, 3, 67–83. [CrossRef]
9. Gustavsson, F.; Buitenhuis, A.J.; Johansson, M.; Bertelsen, H.P.; Glantz, M.; Poulsen, N.A.; Månsson, H.L.; Stålhammar, H.; Larsen,
L.B.; Bendixen, C.; et al. Effects of breed and casein genetic variants on protein profile in milk from Swedish Red, Danish Holstein,
and Danish Jersey cows. J. Dairy Sci. 2014, 97, 3866–3877. [CrossRef]
10. Mclachlan CNS. Beta-casein A1, ischemic heart diseases, mortality and other illnesses. Med. Hypotheses 2001, 56, 262–272.
[CrossRef] [PubMed]
11. Laugesen, M.; Elliott, R. Ischaemic heart disease, Type 1 diabetes, and cow milk A1 beta-casein. N. Z. Med. J. 2003, 116, 1168.
12. Farrell, H.M., Jr.; Jimenez-Flores, R.; Bleck, T.; Brown, M.; Butler, E.; Creamer, K.; Hicks, L.; Hollar, M.; Ng-Kwai-Hang, F.;
Swaisgood, E. Nomenclature of the proteins of cows’ milk—Sixth revision. J. Dairy Sci. 2004, 87, 1641–1674. [CrossRef]
13. Truswell, A.S. The A2 milk case: A critical review. Eur. J. Clin. Nutr. 2005, 59, 623–631. [CrossRef]
14. Kaminski, S.; Cieslinska, A.; Kostyra, E. Polymorphism of bovine beta-casein and its potential effect on human health. J. Appl.
Genet. 2007, 48, 189–198. [CrossRef] [PubMed]
15. Park, Y.W. Hypo-allergenic and therapeutic significance of goat milk. Small Rumin. Res. 1994, 14, 151–159. [CrossRef]
16. Park, Y.W. Goat milk–Chemistry and Nutrition. In Handbook of Milk of Non-Bovine Mammals; Park, Y.W., Haenlein, G.F.W., Eds.;
Blackwell Publishers: Oxford, UK, 2006; pp. 34–58.
17. Alferez, M.J.M.; Barrionuevo, M.; Aliaga, L.L.; Sampelayo, M.R.S.; Lisbona, F.; Robles, J.C.; Campos, M.S. Digestive utilization of
goat and cow milk fat in malabsorption syndrome. J. Dairy Res. 2001, 68, 451–461. [CrossRef]
18. Bevilacqua, C.; Martin, P.; Candalh, C.; Fauquant, J.; Piot, M.; Bouvier, F.; Manfredi, E.; Pilla, F.; Heyman, M. 2000. Allergic
sensitization to milk proteins in guinea pigs fed cow milk and goat milks ofdifferent genotypes. In Proceedings of the 7th
International Conference on Goats, Tours, France, 14–20 May 2000; Gruner, L., Chabert, Y., Eds.; Institute del Elevage Publ.: Tours,
France, 2000; Volume II, pp. 874–879.
19. Podleski, W.K. Milk protein sensitivity and lactose intolerance with special preference to goat milk. In Proceedings of the V
International Conference on Goatss, New Delhi, India, 5–12 May 1992; Volume II, pp. 610–613, Part I.
20. Caroli, A.M.; Chessa, S.; Erhardt, G.J. Invited review: Milk protein polymorphisms in cattle: Effect on animal breeding and
human nutrition. J. Dairy Sci. 2009, 92, 335–5352. [CrossRef]
21. Petrat-Melin, B.; Andersen, P.; Rasmussen, J.T.; Poulsen, N.A.; Larsen, L.B.; Young, J.F. In vitro digestion of purified β-casein
variants A 1, A 2, B, and I: Effects on antioxidant and angiotensin-converting enzyme inhibitory capacity. J. Dairy Sci. 2015, 98,
1–12. [CrossRef]
22. Givens, I.; Aikman, P.; Gibson, T.; Brown, R. Proportions of A1, A2, B and C β-casein protein variants in retail milk in the UK.
Food Chem. 2013, 139, 549–552. [CrossRef]
23. Giglioti, R.; Gutmanis, G.; Katiki, L.M.; Okino, C.H.; Cristinade, M.; Oliveira, S.; Filho, E.V. New high-sensitive rhAmp method
for A1 allele detection in A2 milk samples. Food Chem. 2020, 313, 126167. [CrossRef]
24. Heyman, M.; Grasset, E.; Duroc, R.; Desjeux, J.F. Antigen absorption by the jejunal epithelium of children with cow’s milk allergy.
Pediatr. Res. 1988, 24, 197–202. [CrossRef] [PubMed]
25. Groves, M.I. Some minor components of casein and other phosphoproteins in milk. A revew. J. Dairy Sci. 1969, 52, 1155–1165.
[CrossRef]
26. Roginski, H. Encyclopedia of Dairy Sciences; Academic Press: London, UK, 2003.
27. Jianqin, S.; Leiming, X.; Lu, X.; Yelland, G.W.; Ni, J.; Clarke, A.J. Effects of milk containing only A2 beta casein versus milk
containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior
of people with self-reported intolerance to traditional cows’ milk. Nutr. J. 2016, 15, 45. [CrossRef]
Dairy 2021, 2 200
28. Kostyra, E.; Sienkiewicz-Szapka, E.; Jarmoowska, B.; Krawczuk, S.; Kostyra, H. Opioid peptides derived from milk proteins. Pol.
J. Food Nutr. Sci. 2004, 13, 25–35.
29. Nguyen, D.D.; Johnson, S.K.; Busetti, F.; Solah, V.A. Formation and dedradation of beta-casomorphins in dairy processing. Crit.
Rev. Food Sci. Nutr. 2015, 55, 1955–1967. [CrossRef] [PubMed]
30. Jarmołowska, B.; Bukało, M.; Fiedorowicz, E.; Cie´sli ´nska, A.; Kordulewska, N.K.; Moszy ´nska, M.; Swi ˛atecki, A.; Kostyra, E. Role ´
of milk-derived opioid peptides and proline di-peptidyl peptidase-4 in autism. Spectr. Disord. Nutr. 2019, 11, 87.
31. Gill, H.S.; Doull, F.; Rutherfurd, K.J.; Cross, M.L. Immunoregulatory peptides in bovine milk. Br. J. Nutr. 2000, 84, 111–117.
[CrossRef] [PubMed]
32. Meisel, H.; Bockelmann, W. Bioactive peptides encrypted in milk proteins: Proteolytic activation and thropho-functional
properties. Antonie Van Leeuwenhoek 1999, 76, 207–215. [CrossRef] [PubMed]
33. Hartwig, A.; Teschemacher, H.; Lehmann, W.; Gauly, M.; Erhardt, G. Influence of genetic polymorphisms in bovine milk on the
occurrence of bioactive peptides. International. Dairy Federation. 1997, 2, 459–460.
34. Jinsmaa, Y.; Yoshikawa, M. Enzymatic release of neocasomorphin and beta-casomorphin from bovine beta-casein. Peptides 1999,
20, 957–962. [CrossRef]
35. Cieoelinska, A.; Kaminski, S.; Kostyra, E.; Sienkiewicz-Sz3apka, E. Beta-casomorphin 7 in raw and hydrolysed milk derived from
cows of alternative β-casein genotypes. Milchwissenschaft 2007, 62, 125–127.
36. Nguyen, D.D.; Busetti, F.; Johnson, G.S.S.K.; Solah, V.A. Release of beta-asomorphins during in-vitro gastrointestinal digestion of
reconstituted milk after heat treatment. LWT 2021, 136, 110312. [CrossRef]
37. Rangel, A.H.N.; Zaros, L.G.; Lima, T.C.; Borba, L.H.F.; Novaes, L.P.; Mota, L.F.M.; Silva, M.S. Polymorphism in the Beta Casein
Gene and analysis of milk characteristics in Gir and Guzerá dairy cattle. Genet. Mol. Res. 2017, 16, 1–9. [CrossRef]
38. Muehlenkamp, M.R.; Warthesen, J.J. β-Casomorphins: Analysis in cheese and susceptibility to Proteolytic enzymes from
Lactococcus lactis ssp. cremoris. J. Dairy Sci. 1996, 79, 20–26. [CrossRef]
39. Gaudry, K.D.; Lohner, S.; Schmucker, C.; Kapp, P.; Motschall, E.; Hörrlein, S.; Röger, C.; Meerpohl, J.J. Milk A1β-casein and
health-related outcomes in humans: A systematic re-view. Nutr. Rev. 2019, 77, 278–306. [CrossRef] [PubMed]
40. Dai, R.; Fang, Y.; Zhao, W.; Liu, S.; Ding, J.; Xu, K.; Meng, H. Identification of alleles and genotypes of beta-casein with DNA
sequencing analysis in Chinese Holstein cow. J. Dairy Res 2016, 83, 312–316. [CrossRef] [PubMed]
41. Tailford, K.A.; Berry, C.L.; Thomas, A.C.; Campbell, J.H. A casein variant in cow’s milk is atherogenic. Atherosclerosis 2003, 170,
13–19. [CrossRef]
42. Chia, J.S.L.; McRae, J.L.; Kukuljan, S.; Woodford, K.; Elliott, R.B.; Swinbum, B.; Dwyer, K.M. A1 beta-casein milk protein and
other environmental pre-dis-posing factors for type 1 diabetes. Nutr. Diabetes 2017, 7, 1–7. [CrossRef]
43. He, M.; Sun, J.; Jiang, Z.Q.; Yang, Y.X. Effects of cow’s milk beta-casein variants on symptoms f milk intolerance in Chinese adults:
A multi-centre, randomised controlled study. Nutr. J. 2017, 16, 1–12. [CrossRef]
44. Elliott, R.B.; Harris, D.P.; Hill, J.P.; Bibby, N.J.; Wasmuth, H.E. Type I (insulindependent) diabetes mellitus and cow milk: Casein
variant consumption. Diabetologia 42: 292–296. Atherosclerosis 1999, 170, 13–19.
45. Bell, S.J.; Grochoski, G.T.; Clarke, A.J. Health implications of milk containing beta-casein with the A2 genetic variant. Crit. Rev.
Food Sci. Nutr. 2006, 46, 93–100. [CrossRef]
46. Thakur, N.; Chauhan, G.; Mishra, B.P.; Mendiratta, S.K.; Pattanaik, A.K.; Singh, T.U.; Karikalan, M.; Meshram, S.K.; Garg, L.
Comparative evaluation of feeding effects of A1 and A2 cow milk derived casein hydrolysates in diabetic model of rats. J. Funct.
Foods 2020, 75, 104272. [CrossRef]
47. Cade, R.; Privette, R.; Fregly, M.; Rowland, N.; Sun, Z.; Zele, V. Autism and schizophrenia: Intestinal disorders. Nutr. Neurosci.
2000, 3, 57–72. [CrossRef] [PubMed]
48. Nestle; Nestlé Health Science—Global Headquarters: Vevey, Switzerland, 2020.
49. Haenlein, G.F.W.; Caccese, R. Goat milk versus cow milk. In Extension Goat Handbook; Haenlein, G.F.W., Ace, D.L., Eds.; USDA
Publishing: Washington, DC, USA, 1984; pp. 1–4.
50. Walker, W.A. Pathology of intestinal uptake and absorption of antigens in food allergy. Ann. Allergy 1987, 59, 7–16. [PubMed]
51. Soothill, J.F. Slow Food Allergic Disease. Food Allergy; Chandra, R.K., Ed.; Nutrition Research Education Found: St. John’s, Canada,
1987; pp. 305–310.
52. Haenlein, G.F.W. Goat milk in human nutrition. Small Rumin. Res. 2004, 51, 155–163. [CrossRef]
53. Sabbah, A.; Hassoun, S.; Drouet, M. L’allergie au lait de vache et sa substitution par le lait de chevre. In Proceedings, Colloque
Interets Nutritionnel et Dietetique du Lait de Chevre; Inst. Nat. Rech. Agron. Publ.: Paris, France, 1997; pp. 111–118, No. 81.
54. Fabre, A. Perspectives actuelles d’utilisation du lait de chevre dans l’alimentation infantile. In Proceedings, Colloque Interets
Nutritionnel et Dietetique du Lait de Chevre; Inst. Nat. Rech. Agron. Publ.: Paris, France, 1997; pp. 123–126.
55. Reinert, P.; Fabre, A. Utilisation du lait de chevre chez l’enfant. Experience de Creteil. In Proceedings, Colloque Interets Nutritionnel
et Dietetique du Lait de Chevre; Inst. Nat. Rech. Agron. Publ.: Paris, France, 1997; pp. 119–121.
56. Krieger, E. Personal Communication. 2017. Available online: www.ellie.Krieger.com (accessed on 10 September 2020).
57. CRF. California Research Foundation. 2017. Available online: http:/cdrf.org/2017/02/09/ (accessed on 10 September 2020).
Dairy 2021, 2 201
58. Triple—Hil Sires. Dun-Did Bush Wacker. Farmshine, 41(20):3. USDA, DHIA 1980. Annual Report of Official Dairy Herd Testing
Participation; USDA Publ.: Washington, DC, USA, 2020.
59. Savage, D. A2 milk: Is it really better for you? Holstein. Hub. 2018, 2, 1–3.
60. A2 Corporation. 2006. Available online: http://www.a2corporation.com/index.php/ps_pagename/corporate (accessed on 10
September 2020).